Awareness and Use of Delta-8-THC Cannabis Products in the United States: Findings from National Surveys in 2021 and 2022.

Schauer G.; Iraniparast M.; Hammond D. · Cannabis and cannabinoid research · 2026

**Background & Methods** This cross-sectional survey analyzed data from 69,564 U.S. respondents aged 16-65 years participating in the 2021-2022 International Cannabis Policy Study (ICPS). Participants were assessed for awareness, lifetime use, and past-month use of Delta-8-THC products, with logistic regression models examining correlates including state cannabis legalization status. **Key Findings** • Awareness of Delta-8-THC products increased significantly from 14.5% in 2021 to 21.8% in 2022 (AOR = 1.76, 95% CI = 1.59-1.95, p < 0.001), indicating rapid market expansion and consumer recognition. • Ever use of Delta-8 was substantially higher in states where conventional Delta-9-THC cannabis remained illegal (11.2%) compared to states with medical cannabis legalization (8.5%, AOR = 0.68, p < 0.001) and adult-use recreational legalization (6.5%, AOR = 0.44, p < 0.001), suggesting Delta-8 products serve as substitutes in prohibition jurisdictions. • The diversifying cannabinoid market, particularly hemp-derived products with less than 0.3% Delta-9-THC that circumvent federal restrictions, is experiencing rapid proliferation with minimal regulatory oversight. **Dosage & Administration** Not reported. **Safety & Adverse Effects** Not reported. The abstract emphasizes the need for education regarding "potential health risks of novel hemp-derived products" but does not detail specific adverse effects. **Evidence Quality** This is a descriptive epidemiological survey with notable strengths including a large national sample and longitudinal comparison across consecutive years. However, limitations include reliance on self-reported data, lack of clinical outcome measures, and absence of information on product characteristics, dosing, or adverse health effects. The study provides important surveillance data on emerging market trends but offers limited mechanistic or safety information. As a review-type study based on survey data rather than experimental or clinical design, this represents moderate-level evidence suitable for identifying public health surveillance needs rather than establishing causality or clinical safety profiles. Enhanced regulatory monitoring and controlled studies examining health outcomes are warranted.

More recent cannabis research